Show simple item record

dc.contributor.authorLin, Ziqiang
dc.contributor.authorNeiswender, James
dc.contributor.authorFang, Bin
dc.contributor.authorMa, Xuelei
dc.contributor.authorZhang, Jing
dc.contributor.authorHu, Xiuying
dc.date2022-08-11T08:09:47.000
dc.date.accessioned2022-08-23T16:43:38Z
dc.date.available2022-08-23T16:43:38Z
dc.date.issued2017-04-18
dc.date.submitted2017-09-21
dc.identifier.citationOncotarget. 2017 Apr 18;8(16):26625-26636. doi: 10.18632/oncotarget.15775. <a href="https://doi.org/10.18632/oncotarget.15775">Link to article on publisher's site</a>
dc.identifier.issn1949-2553 (Linking)
dc.identifier.doi10.18632/oncotarget.15775
dc.identifier.pmid28460452
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40337
dc.description.abstractOBJECTIVES: The aim of this study was to systematically evaluate the diagnostic value of cell free DNA (cfDNA) for breast cancer. RESULTS: Among 308 candidate articles, 25 with relevant diagnostic screening qualified for final analysis. The mean sensitivity, specificity and area under the curve (AUC) of SROC plots for 24 studies that distinguished breast cancer patients from healthy controls were 0.70, 0.87, and 0.9314, yielding a DOR of 32.31. When analyzed in subgroups, the 14 quantitative studies produced sensitivity, specificity, AUC, and a DOR of 0.78, 0.83, 0.9116, and 24.40. The 10 qualitative studies produced 0.50, 0.98, 0.9919, and 68.45. For 8 studies that distinguished malignant breast cancer from benign diseases, the specificity, sensitivity, AUC and DOR were 0.75, 0.79, 0.8213, and 9.49. No covariate factors had a significant correlation with relative DOR. Deek's funnel plots indicated an absence of publication bias. MATERIALS AND METHODS: Databases were searched for studies involving the use of cfDNA to diagnose breast cancer. The studies were analyzed to determine sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio (DOR), and the summary receiver operating characteristic (SROC). Covariates were evaluated for effect on relative DOR. Deek's Funnel plots were generated to measure publication bias. CONCLUSIONS: Our analysis suggests a promising diagnostic potential of using cfDNA for breast cancer screening, but this diagnostic method is not yet independently sufficient. Further work refining qualitative cfDNA assays will improve the correct diagnosis of breast cancers.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28460452&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright : © 2017 Lin et al.
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/
dc.subjectAccuracy
dc.subjectbreast cancer
dc.subjectcell-free DNA
dc.subjectdiagnosis
dc.subjectmeta-analysis
dc.subjectCancer Biology
dc.subjectDiagnosis
dc.subjectNeoplasms
dc.subjectOncology
dc.titleValue of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis
dc.typeJournal Article
dc.source.journaltitleOncotarget
dc.source.volume8
dc.source.issue16
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4144&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3137
dc.identifier.contextkey10782020
refterms.dateFOA2022-08-23T16:43:38Z
html.description.abstract<p>OBJECTIVES: The aim of this study was to systematically evaluate the diagnostic value of cell free DNA (cfDNA) for breast cancer.</p> <p>RESULTS: Among 308 candidate articles, 25 with relevant diagnostic screening qualified for final analysis. The mean sensitivity, specificity and area under the curve (AUC) of SROC plots for 24 studies that distinguished breast cancer patients from healthy controls were 0.70, 0.87, and 0.9314, yielding a DOR of 32.31. When analyzed in subgroups, the 14 quantitative studies produced sensitivity, specificity, AUC, and a DOR of 0.78, 0.83, 0.9116, and 24.40. The 10 qualitative studies produced 0.50, 0.98, 0.9919, and 68.45. For 8 studies that distinguished malignant breast cancer from benign diseases, the specificity, sensitivity, AUC and DOR were 0.75, 0.79, 0.8213, and 9.49. No covariate factors had a significant correlation with relative DOR. Deek's funnel plots indicated an absence of publication bias.</p> <p>MATERIALS AND METHODS: Databases were searched for studies involving the use of cfDNA to diagnose breast cancer. The studies were analyzed to determine sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio (DOR), and the summary receiver operating characteristic (SROC). Covariates were evaluated for effect on relative DOR. Deek's Funnel plots were generated to measure publication bias.</p> <p>CONCLUSIONS: Our analysis suggests a promising diagnostic potential of using cfDNA for breast cancer screening, but this diagnostic method is not yet independently sufficient. Further work refining qualitative cfDNA assays will improve the correct diagnosis of breast cancers.</p>
dc.identifier.submissionpathoapubs/3137
dc.contributor.departmentProgram in Molecular Medicine
dc.contributor.departmentDepartment of Molecular Cell and Cancer Biology
dc.source.pages26625-26636


Files in this item

Thumbnail
Name:
15775_232610_6_PB.pdf
Size:
3.161Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright : © 2017 Lin et al.
Except where otherwise noted, this item's license is described as Copyright : © 2017 Lin et al.